Dye & Durham Initiates Review of Strategic Alternatives
In connection with this announcement, the Company has entered into a Cooperation Agreement ("Agreement") with Plantro Ltd. ("Plantro") under which Plantro has agreed to withdraw its special meeting requisition. As part of this agreement, David Danziger, CPA, CA will be appointed to the Board forthwith. Mr. Danziger will also join and serve as Chair of a newly formed Special Committee tasked with leading the strategic review. The Agreement also contains customary standstill provisions and voting commitments.
"Over the past several weeks, the Board has engaged with shareholders to carefully consider Dye & Durham's next steps," said Board Chair Arnaud Ajdler. "We appreciate the constructive and pragmatic engagement that we have had with Plantro and Matt Proud toward our shared goal of enhancing value for the Company's shareholders, and we are pleased to have reached a resolution. We welcome David, whose M&A and accounting expertise and significant public company director experience will be incredibly additive."
"As one of the Company's largest and longest-standing shareholders, we are pleased to have reached a constructive agreement with the Board that provides the basis to thoughtfully pursue a sale of the Company to preserve and maximize value for all shareholders," said Matt Proud, spokesperson for Plantro. "Plantro is appreciative of the efforts of the Board Chair Arnaud Ajdler in developing this collaborative framework. We look forward to remaining an engaged and constructive shareholder."
David Danziger, CPA, CA Biography
David Danziger, CPA, CA, is an experienced finance leader and corporate director with an extensive background in audit, accounting, M&A and management consulting. Previously, he was the Senior Vice President, Assurance, and the National Leader of Public Companies at MNP LLP, Canada's fifth-largest accounting firm. Mr. Danziger continues to serve as a Senior Advisor for MNP LLP working on special projects and supporting the Public Company Audit Team nationally. Mr. Danziger has served as a director for a range of technology, mining and life sciences companies listed on the TSX, TSXV, CSE and NYSE.
About Dye & Durham Limited
Dye & Durham Limited provides premier practice management solutions empowering legal professionals every day, delivers vital data insights to support critical corporate transactions and enables the essential payments infrastructure trusted by government and financial institutions. The company has operations in Canada, the United Kingdom, Ireland, Australia, and South Africa.
Additional information can be found at www.dyedurham.com
Forward-Looking Statements
This press release may contain forward-looking information within the meaning of applicable securities laws, which reflects Dye & Durham's current expectations regarding future events. In some cases, but not necessarily in all cases, forward-looking statements can be identified by the use of forward looking terminology such as "plans", "targets", "expects" or "does not expect", "is expected", "an opportunity exists", "is positioned", "estimates", "intends", "assumes", "appears", "anticipates" or "does not anticipate" or "believes", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might", "will" or "will be taken", "occur" or "be achieved". In particular, statements regarding the review of strategic alternatives, and the potential sale of the Company, divestiture of assets, recapitalization or merger transactions, and the Company's efforts to maximize value for all shareholders are forward-looking statements.
Forward-looking statements are not historical facts, nor guarantees or assurances of future performance but instead represent management's current beliefs, expectations, estimates and projections regarding future events and operating performance. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Dye & Durham's control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the outcome of the strategic review process, the ability to successfully enter into a transaction with a third party relating to the Company, including a potential sale, divesture of assets, recapitalization or merger transaction, and the factors discussed under "Risk Factors" in Dye & Durham's most recent annual information form. Dye & Durham does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Is Coca-Cola's Diversification Into Energy Drinks Gaining Traction?
The Coca-Cola Company 's KO push into the energy drink category is starting to yield results, although it is a gradual build. While the second-quarter 2025 earnings call did not shine the spotlight on energy drinks directly, the company's emphasis on its diversified portfolio, including BODYARMOR and Powerade, signals strategic momentum. Both brands registered volume growth in the second quarter, contributing to Coca-Cola's broader objective of gaining value share for the 17th consecutive quarter. This reflects consumer receptiveness to Coca-Cola's expanding non-soda offerings. The company's innovation agenda also plays a key role. The latest launches, such as Sprite+Tea, though not energy drinks, highlight Coca-Cola's agility in crafting hybrid beverages that tap into evolving tastes for functionality and flavor. This strategy complements its efforts in premium stills and sports hydration — segments that overlap with consumer needs — in the energy category. The company's all-weather approach and accelerated marketing execution have further enhanced visibility and consumer traction for its broader beverage lineup. While Coca-Cola has not yet disrupted the energy drink market on the scale of leaders like Monster Beverage Corporation MNST or Red Bull, its existing brand power, distribution strength and innovation pipeline suggest it is in for the long game. If current execution trends continue, Coca-Cola's diversification into energy beverages may shift from incremental gain to a more commanding presence in the next few quarters. The Rivalry in Energy Drinks Strengthens: Can PEP & MNST Keep Up? As Coca-Cola steadily expands its footprint in the energy drink market, all eyes are on PepsiCo Inc. PEP and Monster Beverage to see if they can keep pace in this increasingly competitive and fast-evolving segment. PepsiCo is intensifying its energy drink strategy with bold moves like acquiring Poppi, a fast-growing prebiotic soda brand, and expanding Sting's global visibility through a multi-year Formula 1 partnership. Gatorade remains central to its sports hydration portfolio, while Propel drives strong growth in functional drinks. With continued investments in zero-sugar, performance beverages and away-from-home channels, PepsiCo is positioning itself for sustained growth in the fast-evolving energy and wellness drink segment. Monster Beverage continues to dominate the energy drink space with a diverse portfolio that includes Monster Energy, Reign Total Body Fuel, Reign Storm, Bang Energy, Predator and Fury. In first-quarter 2025, the company expanded globally with product launches like Monster Ultra Blue Hawaiian and continues to lead in market share across several countries. Monster is also ramping up innovation and expanding affordable brands internationally, positioning itself for global growth and consumer reach. The Zacks Rundown for Coca-Cola KO shares have risen 10.4% year to date compared with the industry 's growth of 5.3%. From a valuation standpoint, Coca-Cola trades at a forward price-to-earnings ratio of 22.04X, significantly higher than the industry's 17.64X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for KO's 2025 and 2026 earnings implies year-over-year growth of 3.1% and 8.3%, respectively. Earnings estimates for 2025 have been unchanged in the past 30 days. Coca-Cola currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. One Big Gain, Every Trading Day To help you take full advantage of this market, you're invited to access every stock recommendation in all our private portfolios - for just $1. Zacks private portfolio services that closed 256 double and triple-digit winners in 2024 alone. That's about one big gain every day the market was open. Of course, not all our picks are winners, but members have seen recent gains as high as +627% +1,340%, and +1,708%. Imagine how much you could profit with a steady stream of real-time picks from all our services that cover a number of strategies to suit a variety of investing and trading styles. See Stocks Now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CocaCola Company (The) (KO): Free Stock Analysis Report
Toronto Star
an hour ago
- Toronto Star
PharmaCorp Announces Filing of Annual Information Form
SASKATOON, Saskatchewan, July 31, 2025 (GLOBE NEWSWIRE) — PHARMACORP RX INC. ('PharmaCorp' or the 'Corporation') (TSXV: PCRX) is pleased to announce that it has voluntarily filed an Annual Information Form ('AIF') for the year ended December 31, 2024 on SEDAR+. An electronic copy of the AIF may be obtained on PharmaCorp's website at or on the Corporation's SEDAR+ profile at
Globe and Mail
an hour ago
- Globe and Mail
Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says
Key Points Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ultra-high dividend make it a good choice for long-term investors. 10 stocks we like better than Pfizer › Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as one of the main vaccine suppliers. That led to its stock price and revenue skyrocketing, and even brought Pfizer's market cap to over $340 billion at one point. Since its late-2021 peak, Pfizer's stock is down over 60%. In the past three years, it's off by 52%, even while beating its earnings per share (EPS) estimates in all 12 reported earnings in that time. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Pfizer will report its fiscal second-quarter earnings on Aug. 5. Although we won't know if it'll continue its beats streak until then, it's probably not a good idea to try to time your investment around the date. Let's take a look at why. There's no correlation between Pfizer's earnings and immediate stock price moves You would think that a company beating its earnings estimates would excite investors and lead to positive stock price movements, but that's unfortunately not how the stock market operates. Other factors influence stock price movements -- such as future guidance, the macroeconomic environment, and overall investor sentiment -- so focusing on earnings alone can misguide you. Even with Pfizer's consistency in beating earnings estimates, history has shown that this hasn't always sent its stock price up. The table below shows its next-day stock price movements after earnings reporting. Reported Quarter Beat EPS Estimates? Positive Next-Day Stock Price Move May 2025 Yes Yes Feb. 2025 Yes No Oct. 2024 Yes No July 2024 Yes Yes May 2024 Yes Yes Jan. 2024 Yes No Aug. 2023 Yes No May 2023 Yes No Data sources: AlphaQuery and YCharts. Regardless of the company, it's helpful to remember this: It's never a good idea to try to time the market, because the market doesn't behave rationally -- at least, in the short term. Pfizer is a good value opportunity If you're looking for reasons to invest in Pfizer, they shouldn't revolve around its upcoming earnings date. Instead, invest because of its cheap valuation and ultra-high dividend yield. Pfizer is currently trading at 8 times its forward earnings, which is less than competitors like Johnson & Johnson, AbbVie, and Eli Lilly, and far below the S&P 500 healthcare sector's 16.5 average. PFE PE Ratio (Forward) data by YCharts. Pfizer's stock has lagged behind the overall market, but this low valuation gives it more long-term upside than downside, in my opinion. We can't predict how its stock will perform in the near-term, but its 7% dividend yield (as of July 29) is a great incentive to keep investors patient. If you're in on Pfizer for the long term, now seems like a good opportunity to begin a stake (or increase your current shares). But if you're looking to make some quick cash from a potential post-earnings swing, you're essentially gambling. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025
